Illumina Innovation Roadmap: Beyond the Genome with Multiomics
Andrew Slatter, Director, Scientific Research, Illumina
Accelerating Translational Health Programs. Integrating Multi Omics for Early Disease Risk Assessment
Ephrem Chin, MBA, BTech(Hon), MB(ASCP), QLC, CGMBS, VP OMICS Services Strategy,
Technical Operations & Commercial, Revvity
Tittle to be announced
Professor Alexander Hoischen, Radboud University Medical Center, Pacific Biosciences
Dawid, a key member of Ardigen's team since 2017, is not just an AI expert but also a visionary leader. While earning his PhD in Artificial Intelligence and Computer Vision from Jagiellonian University, Kraków, he has become a specialist in analyzing high-content images, digital pathology, protein microarrays, and biomedical imaging. Moreover, Dawid's proven project leadership has been instrumental in the success of various initiatives at Ardigen, including groundbreaking multimodal fusion projects. His unique approach to integrating chemical structures with raw images, and combining clinical data with raw imagery, sets new standards in the field of AI-driven biotech.
Dr Maria Dunford is a biotech entrepreneur who has founded two companies: Innovation Forum and Lifebit. As Lifebit’s CEO, Maria has led Lifebit to become one of the industry’s fastest growing companies and the biggest disruptor, securing contracts with high-profile clients across the life sciences sector, including Genomics England and Boehringer Ingelheim. Recently listed as a Top 100 future unicorn to watch by Financial Times’ Sifted, Maria has led Lifebit to raise over $70 million in capital funding, including 95 billion dollar venture capital firm Tiger Global.
Maria’s leadership has been highlighted across multiple outlets, including Beauhurst’s “Top 50 Female Entrepreneurs to Watch for 2022”, Business Leader’s “Top 32 UK’s Biggest Exporters”, and Fortune Greece’s Top “40 under 40”. A frequent speaker at international conferences such as BioData World and high-profile outlets like The Economist and TechCrunch, Maria is a thought leader who is shaping precision medicine and precision drug discovery.
Ephrem is an experienced genOMICS professional and has held various commercial and scientific/technical roles at Auckland District Health Board, Baylor College of Medicine, Emory University, Oxford Gene Technology and Revvity. Ephrem is certified by the American Society for Clinical Pathology in Molecular Biology and Quality & Laboratory Compliance and is licensed as a Clinical Genetic Molecular Biologist Scientist by the California Department of Public Health. He holds a bachelor’s in biotechnology with 1st Class Honors from University of Auckland and a Master’s in Business Administration (MBA) from Emory University’s Goizueta Business School.
Andrew leads an assay technology and product development team at Illumina, focusing on library preparation, multiomics, proteomics, and sequencing applications. Since joining Illumina in 2014, he has developed multiple technologies that are now incorporated into a wide range of Illumina products.
Andrew has a background in biochemistry and molecular biology and received his PhD from UCL, where he studied DNA helicase unwinding mechanisms. He began his biotech career in drug discovery, developing in vitro enzyme assays for drug screening, before joining a Cambridge-based startup focused on innovative sample and library preparation techniques for the rapidly growing NGS field.
Ardigen is a world-leading AI-powered drug discovery CRO bringing transformative AI solutions to biotech and pharma. Our advanced platforms and deep scientific expertise turn data into pivotal insights to accelerate the drug development process and deliver successful therapies to patients faster. With Ardigen, you can seamlessly integrate AI capabilities into your drug discovery pipeline and optimize every step along the way.
At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Our microarrays provide accurate, high-throughput genotyping for a range of applications. The innovative products that we provide have already helped researchers make breakthroughs in many biological areas, including oncology, reproductive health, genetic disease, precision medicine, agriculture, microbiology, and beyond. The progress we see inspires us to push the boundaries of what is possible so we can create the next generation of genomics solutions.
Lifebit is the world’s leading provider of federated Trusted Research Environments. Our Federated Data Network includes 275 million patients from over 50 partners and spans all therapeutic areas and modalities, with a particular focus on molecular and multi-omic data.
Lifebit supports major data organisations like Optum, 23andMe, Flatiron Health, Genuity Sciences, or Cancer Research Horizons and national programs such as the NIH National Library of Medicine, Genomics England, Singapore’s Ministry of Health (TRUST/PRECISE), Israel's National Genome Project Psifas, CanPath and the Danish National Genome Center among others. Generating large amounts of biomedical data has become relatively straightforward. The challenge is finding, accessing, standardising and analysing this sensitive data stored across thousands of disconnected locations. Lifebit solves this challenge with unique and patented federated technology that brings analysis and computation to where data resides. This enables researchers to run analyses on multiple, distributed datasets, in-situ, avoiding the risky movement of highly sensitive data.
At Lifebit, we are on a mission to harness the power of connected data to drive advancements in precision medicine. Advancing life-saving treatments starts with equipping researchers worldwide with the right data, enabling them to advance research, and develop precise therapies, faster.
Oxford Nanopore Technologies’ vision is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that delivers information-rich, rapid, accessible and affordable DNA and RNA analysis. Used in more than 125 countries, it aids in understanding human, plant, animal, bacterial, viral, and environmental biology, as well as a range of diseases including cancer.
Revvity Omics, a part of Revvity, Inc., is the global leader in newborn screening and clinical genomics testing. We are a leading provider of advanced genomic and molecular diagnostic services, dedicated to revolutionizing healthcare through cutting-edge technology and deep scientific expertise. Our comprehensive portfolio encompasses a wide range of testing solutions, including genetic sequencing, biomarker assays, and personalized medicine diagnostics, catering to both clinical and research markets.
At Revvity Omics, we are committed to empowering healthcare providers, pharmaceutical companies, and researchers with the tools they need to advance precision medicine. Our state-of-the-art laboratories are equipped with the latest technologies in next-generation sequencing (NGS), single nucleotide variant (SNV) analysis, copy number variant (CNV) detection, and more, ensuring accurate and reliable results that drive better patient outcomes.
Our Clinical Genomic Services include:
• A full continuum of care, from preconception and prenatal to neonatal, pediatrics, and adult patients.
• Cutting-edge laboratories equipped with the latest instruments and platforms for multi-omics testing.
• A flexible testing menu, including customizable gene panels (AnyPanel™), WholePanel™ (WGS-based panels), whole exome sequencing, and whole genome sequencing to meet diverse testing needs.
Revvity Omics is constantly pushing the boundaries of what’s possible in healthcare. Our mission is to enhance the quality of life through the power of precision diagnostics, offering solutions that are not only comprehensive but also tailored to meet the unique needs of each patient.
Softcat is a leading UK IT infrastructure solutions provider, helping organisations use technology to succeed. We deliver independent advice, design, procurement, implementation and managed services across cloud, cyber security, networking, data, digital workspace and modern infrastructure, working with both public and private sector organisations.
PacBio is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.